Analyst Ratings January 28, 2026

BofA Elevates Microchip to Buy, Cites Recovery Momentum and Broad End-Market Exposure

Analyst lift raises price target to $95 as estimates for CY26/27 climb and product wins across automotive, industrial and data center markets accumulate

By Leila Farooq MCHP
BofA Elevates Microchip to Buy, Cites Recovery Momentum and Broad End-Market Exposure
MCHP

BofA Securities upgraded Microchip Technology from Neutral to Buy and increased its price target to $95 from $78, citing improving recovery momentum and clearer visibility into demand. The firm boosted its CY26 and CY27 EPS estimates, highlighted the company’s significant industrial and aerospace exposure, and pointed to data-center-facing products as drivers for further upside. Analysts have broadly revised earnings estimates higher ahead of Microchip's February 5 quarterly report, even as recent revenue has declined year-over-year.

Key Points

  • BofA upgraded Microchip from Neutral to Buy and set a $95 price target, the highest among the analyst range of $60 to $95.
  • BofA increased CY26 and CY27 EPS estimates to $2.36 and $3.10, respectively, citing stronger recovery momentum; 16 analysts have raised earnings estimates ahead of the Feb. 5 quarterly report.
  • Microchip’s revenue mix includes about 48% industrial exposure with roughly 18% from aerospace and defense, plus double-digit exposure to data centers via PCIe switches, supporting both industrial and AI-related demand.

BofA Securities on Wednesday raised its recommendation on Microchip Technology (MCHP) from Neutral to Buy and boosted its target price to $95, up from $78. The revised target sits at the top end of the analyst target range for the stock, which spans from $60 to $95. At the time of the report, Microchip shares were trading at $75.16, close to a 52-week peak of $79.50.

The upgrade reflects BofA’s higher forward-profit expectations for the company. The firm increased its calendar-year 2026 and 2027 earnings-per-share estimates by 8% and 13%, respectively, to $2.36 for CY26 and $3.10 for CY27, citing what it described as stronger recovery momentum and improved visibility into Microchip’s business.

Market analysts appear to be warming to the chipmaker: data compiled ahead of the company’s next quarterly release on February 5 show 16 analysts have revised their earnings forecasts upward for the coming periods. That trend underpins the more constructive outlook from BofA.

BofA highlighted Microchip’s end-market diversification as a key strength. Roughly 48% of the company’s revenue is tied to industrial markets, with approximately 18% coming from aerospace and defense. The firm noted Microchip is likely the largest supplier of aerospace and defense chips, a position that supports stable, mission-critical demand.

Despite that exposure, Microchip has faced revenue pressure recently: trailing-12-month revenue is down 23.36%. Nevertheless, the company has continued to return cash to shareholders, maintaining dividend payments for 24 consecutive years and raising its dividend for 14 straight years, with the yield at 2.42% at the time of the report.

BofA also pointed to Microchip’s double-digit exposure to data centers, calling out products such as PCIe switches that the firm said are well-positioned for AI cluster deployments. That data-center positioning, combined with industrial and aerospace demand, was cited as a contributor to a strong total-shareholder return of 37.76% over the past year.

On profitability, BofA suggested there is room for margin recovery. The firm noted current EBIT margins of roughly 24-27% could move back toward prior peaks above 40%, assuming ongoing improvement in product gross margins and disciplined operations. In a longer-term scenario, BofA saw the possibility of Microchip achieving EPS nearer $4, compared with its CY27 estimate of $3.10.

Separately, an analysis flagged that Microchip appears overvalued relative to its calculated Fair Value at current market levels, while assigning the company a financial health score of "Fair." The analysis and BofA’s projections together present a mixed picture: upside from operating leverage and product positioning alongside valuation and recent revenue weakness.

Microchip has also moved to expand and diversify its product portfolio. The company extended its maXTouch M1 family of touchscreen controllers to cover a wider set of automotive displays, including emerging panel technologies such as OLED and microLED. In power-management, Microchip introduced a lineup of 600V gate drivers engineered for high-voltage applications, offered in multiple configurations and current-drive options.

In product developments aimed specifically at aerospace and defense, Microchip launched its JANPTX family of non-hermetic plastic Transient Voltage Suppressor devices, achieving a first in MIL-PRF-19500 military qualification for such a package. These components are designed to provide transient protection while presenting a lower-cost alternative to traditional, hermetic packages.

Other brokerages have echoed more positive stances. Stifel raised its price target to $90, pointing to diversified revenue streams and capabilities in high-performance analog and embedded computing. Piper Sandler moved its target to $85, citing improving order momentum in industrial markets and stabilization in automotive demand.

The combination of upgraded analyst estimates, expanded product offerings in automotive and power systems, and exposure to data-center AI infrastructure underpin the recent positive reassessment of Microchip. At the same time, the company faces the challenge of converting that positioning into consistent revenue growth after a significant year-over-year decline.

Risks

  • Recent revenue decline - Microchip’s trailing-12-month revenue is down 23.36%, indicating near-term top-line weakness that could constrain margin recovery and investor returns.
  • Valuation concerns - Analysis indicates the stock may be overvalued relative to its Fair Value at current market levels, which could limit upside despite operational improvements.
  • Financial health and margin volatility - The company’s financial health score is rated as "Fair," and restoring EBIT margins from 24-27% back toward previous peaks above 40% is uncertain and depends on product gross-margin improvement and operational discipline.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026